U.S. Markets close in 5 hrs 8 mins

Bristol-Myers tumbles as its $74 billion merger with Celgene faces setback

Bristol-Myers announced plans to divest one of Celgene's most profitable drugs, Otezla, in an effort to speed up approval of the pending $74 billion merger between the two companies. Yahoo Finance's Emily McCormick joins Seana Smith on 'The Ticker' to discuss.